ZYNE — Zynerba Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
Brief: Zynerba Pharmaceuticals Announces Publication In The Journal Of Neurodevelopmental Disorders Describing The Role Of The Endocannabinoid System And Cannabidiol Therapy In Fragile X Syndrome
U.S. STOCKS ON THE MOVE-Nike, Venus Concept, Zymeworks
U.S. STOCKS ON THE MOVE-Nike, Venus Concept, Core Scientific, Zymeworks
U.S. STOCKS ON THE MOVE-Tesla, Nike, Zynerba Pharmaceuticals
Zynerba delays data from genetic disorder drug study on enrollment challenge
Zynerba delays genetic disorder drug data on enrollment challenge (updated)
Zynerba Pharmaceuticals delays data on genetic disorder drug study
Brief: Zynerba Pharmaceuticals Announces Update On RECONNECT, Pivotal Phase 3 Trial Of Zygel
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba
Zynerba rises on positive long-term data from genetic disorder trial
Brief: Zynerba Pharmaceuticals Announces Positive Long-Term Data From Phase 2 INSPIRE Trial In 22q11.2 Deletion Syndrome
Brief: Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation For Zygel In 22Q11.2 Deletion Syndrome
Brief: Zynerba Pharmaceuticals Reports Q3 Results And Operational Highlights
Zynerba Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Zynerba Pharmaceuticals Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Zynerba Pharmaceuticals Announces Issuance Of New U.S. Patent For Zygel For Treatment Of 22q11.2 Deletion Syndrome
U.S. STOCKS ON THE MOVE-Alvotech, Verizon, Lyft, BofA
U.S. STOCKS ON THE MOVE-Gold miners, Protera, Sorrento
U.S. STOCKS ON THE MOVE-Bank of America, Archaea, Roblox